High-capacity low-temperature centrifuge for bioimmunotherapy

Release time:

2012-02-14


Overview:

The GMP laboratory of the Tumor Biotherapy Department is equipped with a cell separator, a high-speed refrigerated centrifuge, a biosafety cabinet, a CO2 incubator, a large-capacity low-temperature centrifuge, an autoclave, an inverted fluorescence microscope, and an ultra-low-temperature freezer at -80℃.

Pancreatic cancer is one of the most common malignant tumors. Because its early symptoms are often subtle and non-specific, by the time it’s detected, the disease has usually progressed to the middle or late stages. Patients with pancreatic cancer in the middle or late stages typically experience a significantly reduced quality of life, often accompanied by a range of symptoms such as abdominal pain, ascites, and fatigue. According to recent studies, immunotherapy has shown remarkable efficacy against pancreatic cancer: after several treatment cycles, patients have demonstrated improved survival rates with no signs of recurrence or metastasis.

  The primary routes of metastasis in pancreatic cancer are lymphatic spread and direct infiltration, followed by hematogenous dissemination and spread along nerve sheaths. At the time of diagnosis, only about 10% of patients have tumors that remain localized; 90% of patients already have metastases, with more than 50% having liver metastases, 25% exhibiting mesenteric metastases, and over 20% invading the duodenum. Notably, pancreatic cancer tends to metastasize primarily along nerve pathways—a biological characteristic that distinguishes it from other gastrointestinal tumors. A follow-up study involving 34 pancreatic cancer patients revealed that in 97% of these patients, tumor metastases occurred along nerve pathways, a rate higher than that of lymphatic spread (76%).

  It’s not hard to imagine that patients with advanced or late-stage pancreatic cancer suffer tremendously and have a very low quality of life—especially those facing metastasis and recurrence, for whom the situation only grows worse. Currently, the most effective treatment approach is cellular immunotherapy; statistics show that among patients treated with this method, 78% survive for more than five years without experiencing malignant phenomena such as metastasis or recurrence.

  Cellular immunotherapy primarily involves extracting human immune cells—DCs and CIKs—from the body, culturing them in a laboratory, and then reinfusing them into the patient. These anti-tumor cells (DCs/CIKs) can significantly inhibit the growth and proliferation of cancer cells. Not only do they efficiently and precisely kill tumor cells, but they also stimulate the body to mount an anti-tumor immune response, enabling the immune system to function normally and eliminate tumor cells. Additionally, this therapy activates immune surveillance mechanisms, helping to prevent tumor metastasis and recurrence.

The GMP Laboratory of the Tumor Biological Therapy Department is equipped with advanced therapeutic devices and facilities for tumor bioimmunotherapy, including a cell separator, a high-speed refrigerated centrifuge, a biosafety cabinet, a CO2 incubator, a large-capacity low-temperature centrifuge, an autoclave, an inverted fluorescence microscope, an ultra-low-temperature freezer at -80℃, a flow cytometer, and an enzyme-linked immunosorbent assay (ELISA) reader.